Incyte Corporation
INCY
Last
$112.79
Day
+0.0%
1y
+33.0%
5y
+70.0%
52w
-15.0%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-10-2717d
EMA 21
119.16
EMA 50
120.04
EMA 200
108.49
20d high
-12.4%
5y high
-15.0%
5y range
76th
Positions held
Your positionsINCY isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-16
Hold
avoid
Signal
Strong Sell
Target
$118.84
Stop
$107.67
Stop distance
4.5%
Target vs last
+5.4%
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
Bull case
- Incyte Corporation is well-positioned in the biotechnology industry, focusing on innovative therapies that address unmet medical needs, which can lead to significant market opportunities.
- In Q2 2026, Incyte reported a revenue of $1.7 billion, a 32% increase compared to the previous quarter.
- The company's gross margin improved to 93.7% in Q2 2026, up from 91.8% in Q1 2026.
Bear case
- The competitive landscape in biotechnology is intense, with numerous companies vying for market share, which can pressure pricing and margins.
- Incyte's stock has a 'Strong Sell' signal with a score of -19.00, indicating bearish sentiment among analysts.
- The operating margin decreased to 25.5% in Q4 2025 from 31.6% in Q3 2025, reflecting potential operational challenges.
Fundamentals
| Market cap | $22.85B | Enterprise value | $18.36B | Trailing P/E | 14.36 | Forward P/E | 12.89 |
| PEG | 10.82 | Price / book | 3.57 | Beta | 0.74 | Dividend yield | 0.00% |
| Revenue growth | 37.7% | Earnings growth | 37.7% | Gross margin | 55.7% | Operating margin | 41.9% |
| Profit margin | 27.7% | ROE | 30.7% | ROA | 16.8% | Debt / equity | 0.01 |
| Current ratio | 4.59 | Free cash flow | $1.18B | Analyst recommendation | buy | Mean target | $129.13 |
| 52w high | $132.60 | 52w low | $82.82 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.3B | $1.5B | $1.4B | $1.2B | — |
| Op margin | 41.8% | 25.5% | 25.5% | 31.6% | 25.6% | — |
| Net income | $586M | $303M | $299M | $424M | $405M | — |
| Gross margin | 93.7% | 91.8% | 92.0% | 92.8% | 93.5% | — |
| Gross profit | $1.6B | $1.2B | $1.4B | $1.3B | $1.1B | — |
| Operating income | $700M | $324M | $384M | $431M | $311M | — |
- Revenue +32% vs prior quarter ($1.7B vs $1.3B).
- Gross margin 93.7% (was 91.8% prior quarter).
- Operating margin expanded to 41.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.1B | $4.2B | $3.7B | $3.4B | — |
| Op margin | 26.1% | 2.4% | 17.7% | 17.4% | — |
| Net income | $1.3B | $32.6M | $598M | $341M | — |
| Gross margin | 92.8% | 92.6% | 93.1% | 93.9% | — |
| Gross profit | $4.8B | $3.9B | $3.4B | $3.2B | — |
| Operating income | $1.3B | $101M | $655M | $592M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
No headlines.
Price (daily)
Full chart · RSI · MACD · patternsINCY · daily+36.3% over 260 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin
Chart patterns
Actionable setups from the latest nightly S&P 500 scan.
- 73%
Double Top
bearish
- Completed
- Aug 24, 2026
- Trigger
- 115.77
Neckline 115.77; highs 132.60/130.80 over 20 bars; measured move ~15.93
View on chart →